Vycor Medical (OTCMKTS:VYCO) is a medical device company focused on the design, development and commercialization of minimally invasive surgical technologies for the treatment of neurological disorders. Founded in 2005 and headquartered in Boca Raton, Florida, the company’s mission centers on improving patient outcomes by enabling surgeons to access delicate brain and spinal tissue through tubular retraction systems. Over its history, Vycor Medical has secured FDA clearances and established a robust intellectual property portfolio to support its innovation pipeline.
The company’s flagship product, the ViewSite Brain Access System, is a transparent, tubular retractor that allows neurosurgeons to create a precise corridor to deep-seated lesions while minimizing trauma to surrounding tissue. In addition to its cranial applications, Vycor offers access solutions for spinal procedures, with instruments designed to facilitate decompressions and biopsies through small incisions. These platforms are complemented by a range of ancillary accessories, including obturators and sheaths, which enhance surgical visualization and control intraoperative bleeding.
Vycor Medical markets its products in North America, Europe and select markets in Asia and Latin America through direct sales forces and distribution partnerships. The company collaborates with leading academic medical centers to conduct clinical evaluations and surgeon training, helping to expand adoption of minimally invasive neuro-access techniques. Regulatory efforts continue to advance new indications, including treatments for intracerebral hemorrhage and other complex neurological conditions.
Leadership at Vycor Medical comprises professionals with extensive experience in medical device commercialization and neurosurgical technology. The executive team is supported by contributions from key opinion leaders in neurosurgery and a board of directors that guides strategic investments in research and development. As Vycor Medical pursues next-generation innovations, it remains committed to delivering technologies that reduce operative risk and improve quality of life for patients worldwide.
